What Pericam Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms across domains where additional symptomatic support is needed. Its therapeutic scope primarily addresses conditions characterized by periods of heightened symptoms. Its clinical applications include managing Schizophrenia and the manic and mixed episodes of Bipolar I Disorder. It is also applied in an adjunctive capacity for both the depressive phase of Bipolar I Disorder and cases of treatment-resistant depression.

In clinical scenarios, Pericam is relevant when symptoms become temporarily overwhelming, such as during phases of acute psychotic or mood instability. It helps address symptom clusters that may become intense or disruptive, including hallucinations, delusions, and symptoms related to heightened physiological activity. The medication supports the patient during difficult episodes by contributing to easing the overall symptom load and may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Acute Distress
Commonly used to help with	Extreme agitation associated with psychotic or manic states.
Symptomatic support	Supports short-term stabilization and contributes to easing the overall symptom load.
Relevant context	Applied in clinical settings that involve acute or unstable symptom patterns.

Eligibility Map: Who Can and Cannot Use Pericam (Olanzapine) — Official Regulatory Information

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Adults (age 18 years and older) are eligible for all approved uses. Adolescents (ages 13 to 17 years) are eligible for specific uses, including Schizophrenia and Bipolar I Disorder (manic or mixed episodes).
• Populations for whom use is not recommended (if applicable): Use is generally not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus. Breastfeeding is not recommended as the substance is excreted in human milk.
• Populations for whom use is contraindicated: Use is absolutely prohibited in patients with a known hypersensitivity to Olanzapine. It is also strictly contraindicated for use in elderly patients with dementia-related psychosis.

Age-Related Eligibility Rules

• Children (Under 13): Safety and effectiveness have not been established.
• Geriatric Patients (65+): Contraindicated in those with dementia-related psychosis; caution is advised for other older adults.

Condition-Specific Eligibility Rules

• Organ Impairment: Patients with hepatic impairment (e.g., moderate hepatic insufficiency) or renal impairment should use the medicine with caution.
• Comorbid Conditions: Conditional use is required for patients with conditions such as untreated narrow-angle glaucoma, pre-existing cardiovascular disease, or known risk factors for hypotension.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define eligibility through a framework that establishes contraindications for high-risk groups and specifies conditional use for others, such as those with organ impairment or age-related factors. The profile is structured by age and comorbidity to ensure the medicine is only used where safety and efficacy are officially documented.

Pericam Interactions with other medicines and products

This section details officially documented interaction patterns based on governmental regulatory sources.

Pharmacokinetic and Metabolic Interactions

Pericam's clearance from the body is significantly affected by medicines that influence the CYP1A2 enzyme pathway. Regulatory labeling notes that the CYP1A2 inhibitor Fluvoxamine can increase Olanzapine levels. Conversely, the CYP1A2 inducer Carbamazepine and smoking (tobacco use) can decrease Olanzapine exposure by accelerating its removal. Activated Charcoal significantly reduces the oral absorption of Pericam and must be separated in administration time.

Pharmacodynamic and Co-administration Restrictions

Caution is advised when co-administering Pericam with other Centrally Acting Medicines and alcohol due to the potential for additive CNS effects, such as increased sedation. Similarly, co-use with drugs possessing anticholinergic activity may increase additive anticholinergic effects. The co-administration of intramuscular Olanzapine and Benzodiazepines is officially noted in regulatory documents to be not recommended.

Population and Timing Notes

Interaction severity and resulting Olanzapine exposure may be heightened in specific populations, such as non-smoking female patients over 65 years of age, according to official documentation. The interaction with Activated Charcoal necessitates a timing separation of at least two hours.

Pericam's effect is driven by broad-spectrum antagonism across several key receptors in the central nervous system (CNS). The core mechanism involves simultaneous antagonism of Dopamine D2 and Serotonin 5 -HT2A receptors, modulating chemical signaling within circuits associated with emotion and thought processes. The combined antagonism facilitates the attenuation of heightened neural activity, altering the overall physiological response.

The drug also blocks Histamine H1 receptors, initiating a central cascade that results in a profound reduction of arousal signaling, leading to a physiological consequence of CNS depression and reduced arousal. Separately, antagonism of Alpha-1 adrenergic receptors modulates the autonomic control of peripheral blood vessels, influencing pressure regulation. For the Intramuscular route, the mechanism facilitates rapid achievement of CNS receptor saturation. However, the molecule's broad affinity profile is mechanistically linked to changes in metabolic signaling.

Pericam is a genetically-encoded fluorescent indicator, which means it is an investigational tool used exclusively for research and laboratory procedures to visualize and measure calcium ion (Ca^2+) dynamics within living cells.

It is not a pharmaceutical drug for patient use, nor is it a medical device, and therefore it does not have a standard dosage or administration schedule, as it is not intended for patient treatment.

---

Principle of Administration in Research

The use of Pericam is specific to the experimental protocol being performed. In general, its application involves several precise steps for cellular imaging:

1. Preparation: The Pericam gene construct is typically introduced into cells (e.g., HeLa cells or cardiomyocytes) using transfection techniques.
2. Expression: Cells are allowed to express the Pericam protein for a specified period (e.g., 1–2 days) to ensure adequate concentration in the target cellular compartment, such as the cytosol or mitochondria.
3. Imaging: The cells are then imaged using fluorescence microscopy—often a confocal or wide-field system equipped with specific excitation and emission filters. Ratiometric Pericam variants, for example, require alternating excitation at different wavelengths (e.g., 495 nm and 380 nm) to quantify the Ca^2+ concentration ratio.

The signal intensity changes in response to free Ca^2+ binding, allowing researchers to monitor dynamic events like Ca^2+ oscillations. Pericam is strictly for controlled laboratory research applications and is not available or intended for self-administration or clinical use.

Pericam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, commonly recognized by its generic name, piroxicam. Clinical studies primarily focus on its use in managing chronic inflammatory conditions, particularly the symptoms associated with osteoarthritis (OA) and rheumatoid arthritis (RA).

Therapeutic Focus

Clinical trials have established Pericam's role in providing relief for symptoms of both OA and RA. The therapeutic effects, including pain relief and reduction of inflammation, have been observed to increase progressively over a period of several weeks, typically spanning 8 to 12 weeks of continuous use. Its long half-life, which supports once-daily dosing in clinical practice, has been studied as a potential factor for improved patient adherence compared to NSAIDs requiring multiple daily doses.

Efficacy Data

Comparative clinical data suggests that Pericam (at a standard adult dose of 20 mg/day) demonstrates a therapeutic effect comparable to other established anti-inflammatory treatments used for OA and RA. Studies involving acute conditions, such as low-back pain, have shown that Pericam was associated with greater pain relief in the initial days of treatment (e.g., after 3 days) compared to placebo, although this difference may not be sustained after a full week of therapy.

Safety and Post-Marketing Surveillance

Due to its classification as an NSAID, clinical and post-marketing surveillance data underscore the importance of monitoring for serious potential risks, particularly gastrointestinal complications (such as ulceration and bleeding) and cardiovascular events (such as heart attack or stroke), especially with long-term use. The European Medicines Agency (EMA) and other regulatory bodies have recommended limiting its use to the treatment of chronic inflammatory conditions where the benefit-risk profile is considered favorable.

Common questions about Pericam (FAQ)

Q: Is Pericam the same kind of medicine as aspirin?

Pericam, in its Piroxicam component, belongs to the same general class of medicines as aspirin, which are non-steroidal anti-inflammatory drugs (NSAIDs). However, official product information identifies Piroxicam as a specific type of NSAID known as the oxicam class, meaning it is a different specific compound and not identical to aspirin.

Q: How does Pericam fit into treating long-term conditions?

Pericam is used in the management of chronic conditions, although its components target different diseases. The Piroxicam component is officially indicated for long-term use in conditions like osteoarthritis and rheumatoid arthritis. Separately, the Olanzapine component is used as a maintenance treatment for mental stabilization in disorders such as Schizophrenia and Bipolar I Disorder.

Q: Is a headache a reported side effect of Pericam?

Yes, regulatory source data indicates that headache is a commonly reported side effect for the active ingredients that make up Pericam. This information is included in the official safety profile for the medication.

Q: Can Pericam affect sleep patterns?

The Olanzapine component of Pericam can affect rest. Official information notes that it can cause somnolence (sleepiness) as a very common side effect, and in some cases, it can be associated with insomnia. These documented effects may influence an individual's normal sleep patterns.

Q: How long after starting Pericam do people typically notice changes?

The time frame for noticing initial changes depends on the component being used and the condition being treated. For the Olanzapine component, improvements may become noticeable within one to two weeks. For the Piroxicam component, the full therapeutic effect may be observed over several weeks of use, as documented in studies.

Q: Does Pericam need to be taken consistently to work?

The official guides mention taking the medication consistently, often at the same time every day. Patients are generally described as needing to continue the medication unless instructed otherwise by their prescribing professional.

Q: Is Pericam available without a prescription in some countries?

In the United States, the active ingredient in Pericam, Olanzapine, is classified as a prescription-only medicine. Official regulatory documents from major global agencies categorize the medication for prescription use, but specific availability rules may differ by country.

Q: Can Pericam be taken by people who are sensitive to other NSAIDs?

Official labeling for the Piroxicam component states that it is contraindicated (absolutely prohibited) for use in patients who have experienced allergic reactions such as asthma or hives after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Are there any food restrictions mentioned for people taking Pericam?

According to the official product information for the Olanzapine component, the medication may generally be taken with or without food. There are no specific food restrictions that are noted in the regulatory labeling.

Q: What happens if a person forgets to take a dose of Pericam?

Regulatory patient information describes the general procedure of taking the missed dose as soon as it is remembered. However, if it is close to the next scheduled dose, the regulatory information describes the process of skipping the missed dose to avoid taking two doses too close together.

Q: Are there official restrictions on how long Pericam can be taken?

Official product information describes the use of the Piroxicam component for the shortest duration possible. This is due to the documented increase in risk of potential cardiovascular and gastrointestinal events associated with the long-term use of NSAIDs.

Q: Can Pericam be crushed or split?

Official documentation states that regular Olanzapine tablets are designed to be swallowed whole and should not be crushed or split. Similarly, the orally disintegrating tablets (ODTs) are specifically designed to dissolve quickly in the mouth and must not be crushed, cut, or chewed.

Q: Does Pericam have a risk of dependency or addiction?

The Olanzapine component is not classified as an addictive substance. However, like many medications that affect the central nervous system, regulatory and medical sources note that patients can develop a physical dependence, meaning abrupt discontinuation can lead to temporary withdrawal-like symptoms.

Q: What kind of medical monitoring is required while taking Pericam?

Regular medical monitoring is required for patients taking Pericam due to potential systemic effects. This typically involves check-ups to track changes in blood pressure, monitor blood sugar (glucose) levels, and assess cholesterol and triglyceride levels, as these can be affected by the Olanzapine component.

Q: Is it okay to drive or operate machinery while taking Pericam?

Official labeling indicates the potential for impaired judgment, and patients are generally advised to exercise caution when driving or operating machinery until they know how the medication affects them.

Q: What if I take Pericam and then start another new medication?

If starting any new medicine, including over-the-counter drugs or herbal supplements, official product information advises patients to inform their healthcare provider. This is necessary to review all current medications together to check for potential drug interactions that may change how Pericam works.

Q: Can Pericam be used alongside natural health supplements?

Medication guides advise that patients share a list of all supplements, including natural health products and vitamins, with a healthcare professional. This allows them to check for any possible interactions that could affect the safety or effectiveness of Pericam.

Q: Is there a specific patient information leaflet (PIL) for Pericam that is easy to find?

Yes, a special patient-focused document, often called a MedGuide or Patient Information Leaflet, is provided by the dispensing pharmacist with each new prescription and refill. This document contains key safety and usage information required by regulatory bodies.

How to Store and Dispose of Pericam (Olanzapine)

Storage of Pericam requires adherence to specific labeled conditions to maintain product stability. Oral forms must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from both light and moisture. The Orally Disintegrating Tablets (ODTs) must remain sealed in their blister packaging until the moment of use. For the injectable solution, reconstitution is followed by a short one-hour stability period, requiring immediate administration.

All forms of the medicine must be stored out of the sight and reach of children.

Disposal should utilize a drug take-back program. If unavailable, the product must be mixed with an undesirable substance (such as cat litter), sealed, and placed in household trash; the product must not be flushed into wastewater.